Ex-GSK China researchers hit back
This article was originally published in Scrip
The Chinese GlaxoSmithKline scientist who resigned in relation to alleged "misrepresentation of data" in a leading science journal has claimed not only that the data were authentic and reproducible but has also suggested that the internal investigation by the pharma firm may have been unbalanced.
You may also be interested in...
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.
Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings
Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.